1 はじめに 20
1.1 調査目的 20
1.2 市場の定義 20
1.3 調査範囲 21
1.3.1 対象市場と地域範囲 21
1.3.2 対象範囲と除外範囲 22
1.3.3 考慮した年数 22
1.4 考慮した通貨 23
1.5 利害関係者 23
2 調査方法 24
2.1 調査データ 24
2.1.1 二次データ 25
2.1.1.1 二次資料からの主要データ 26
2.1.2 一次データ 26
2.1.2.1 一次資料 26
2.1.2.2 一次資料からの主要データ 27
2.1.2.3 主要な業界インサイト 28
2.1.2.4 一次インタビューの内訳 28
2.2 市場規模の推定 29
2.2.1 ボトムアップアプローチ 29
2.2.1.1 アプローチ1：企業収益推定アプローチ 30
2.2.2 トップダウンアプローチ 35
2.3 市場の内訳とデータの三角測量 36
2.4 市場シェア分析 37
2.5 調査の前提 37
2.6 成長率の前提 37
2.7 調査の限界 38
2.7.1 方法論に関する限界 38
2.7.2 範囲に関する限界 38
2.8 リスク評価 38
3 エグゼクティブ・サマリー 39
4 プレミアムインサイト 43
4.1 融合生検市場の概要 43
4.2 北米：融合生検市場：用途別、国別（2023年） 44
4.3 融合生検市場：地理的成長機会 44
4.4 融合生検市場：地域ミックス（2024-2029年） 45
4.5 融合生検市場：先進国vs. 発展途上市場
5 市場の概要 46
5.1 はじめに 46
5.2 市場ダイナミクス 46
5.2.1 推進要因 47
5.2.1.1 前立腺がんの有病率の増加と老年人口の増加 47
老人人口の増加 47
5.2.1.2 官民による償還と投資の利用可能性
および民間部門による投資の可能性 48
5.2.1.3 低侵襲手術の普及率上昇 48
5.2.2 阻害要因 49
5.2.2.1 融合生検システムの高コスト 49
5.2.2.2 融合生検の代替法 49
5.2.3 機会 50
5.2.3.1 新興国における前立腺がんの有病率の上昇 50
5.2.3.2 融合生検装置の技術進歩 50
5.2.4 課題 51
5.2.4.1 熟練した専門家の不足 51
5.2.4.2 一部の国における償還の制限 52
5.3 価格分析 52
5.3.1 価格分析（地域別） 52
5.3.2 価格分析、製品別 53
5.4 バリューチェーン分析
5.5 サプライチェーン分析 54
5.6 エコシステム分析 55
5.6.1 融合生検市場：エコシステムにおける企業の役割 56
5.7 ポーターの5つの力分析 57
5.7.1 新規参入の脅威 58
5.7.2 代替品の脅威 58
5.7.3 買い手の交渉力 58
5.7.4 供給者の交渉力 59
5.7.5 競合の激しさ 59
5.8 主要ステークホルダーと購買基準 59
5.8.1 購入プロセスにおける主要ステークホルダー 59
5.8.2 購入基準 60
5.9 規制情勢 61
5.9.1 北米 61
5.9.1.1 米国 61
5.9.1.2 カナダ
5.9.2 欧州 62
5.9.3 アジア太平洋 63
5.9.3.1 日本 63
5.9.3.2 中国 64
5.9.3.3 インド 65
5.9.4 ラテンアメリカ 66
5.9.4.1 ブラジル 66
5.9.4.2 メキシコ 66
5.9.5 中東 66
5.9.6 アフリカ 67
5.9.7 規制機関、政府機関、その他の組織のリスト 67
その他の組織のリスト 67
5.10 貿易分析 69
5.10.1 融合生検市場の貿易分析 69
5.11 特許分析 70
5.12 2024～2026年の主要会議・イベント 71
5.13 顧客のビジネスに影響を与えるトレンド／混乱 72
5.14 技術分析 73
5.14.1 主要技術 73
5.14.1.1 MRI超音波フュージョンイメージング 73
5.14.2 補完技術 73
5.14.2.1 リキッドバイオプシー 73
5.14.2.1.1 デジタル液滴PCR 73
5.14.2.1.2 タグ付きアンプリコンディープシーケンス 74
5.15 投資と資金調達のシナリオ 74
5.16 融合生検市場におけるジェネレーティブ人工知能の影響 74
6 融合生検市場：ルートタイプ別 75
6.1 導入 76
6.2 経直腸 76
6.2.1 深刻な感染の可能性が高まり市場成長を阻害
市場成長を妨げる 76
6.3 経会陰型 78
6.3.1 MRIと超音波の組み合わせによるがん検出の向上が市場成長を促進 78
6.4 その他のルートタイプ 80
7 融合生検市場、用途別 83
7.1 導入 84
7.2 前立腺がん 84
7.2.1 正確で信頼性の高い前立腺融合生検結果が市場成長を加速 84
7.3 その他の用途 87
8 融合生検市場、製品別 89
8.1 導入 90
8.2 装置 90
8.2.1 多額の初期投資が市場成長を確実なものに 90
8.3 消耗品 93
8.3.1 市場成長を促進する革新的技術と方法論の適用の増加 93
9 融合生検市場：エンドユーザー別 96
9.1 導入 97
9.2 病院 97
9.2.1 迅速かつ正確な診断に対する需要の高まりが市場成長を促進 97
市場成長を促進 97
9.3 その他のエンドユーザー 99
10 融合生検市場、地域別 102
10.1 はじめに 103
10.2 北米 103
10.2.1 北米のマクロ経済見通し 104
10.2.2 米国 107
10.2.2.1 がん研究への資金援助と技術的に進んだ製品の入手可能性が市場成長を促進 107
10.2.3 カナダ 109
10.2.3.1 先進的診断ソリューションに対するニーズの高まりが市場を牽引 109
10.3 欧州 111
10.3.1 欧州のマクロ経済見通し 112
10.3.2 ドイツ 114
10.3.2.1 医療費の増加と癌罹患率の増加が市場成長を促進 114
10.3.3 英国 116
10.3.3.1 臨床インフラの充実が融合生検の普及を加速 116
10.3.4 フランス 118
10.3.4.1 効果的な償還政策と手術製品メーカーに対する政府の支援が市場を拡大 118
10.3.5 イタリア 120
10.3.5.1 老年人口の医療需要の増加が市場成長を支える 120
市場成長を支える 120
10.3.6 スペイン 122
10.3.6.1 医療インフラの改善と老人人口の増加が市場を後押し 122
10.3.7 その他のヨーロッパ 124
10.4 アジア太平洋地域 127
10.4.1 アジア太平洋地域のマクロ経済見通し 127
10.4.2 中国 130
10.4.2.1 中間層の可処分所得の増加と診断手技の増加が市場を押し上げる 130
10.4.3 日本 132
10.4.3.1 堅牢な医療制度と正確な早期がん発見のニーズの高まりが市場成長を支える 132
10.4.4 インド 134
10.4.4.1 患者数の多さと医療投資の増加が
市場への投資の増加 134
10.4.5 その他のアジア太平洋地域 136
10.5 ラテンアメリカ 139
10.5.1 インフラ整備への関心の低さと資源配分の悪さが市場成長の妨げになる可能性 139
10.5.2 ラテンアメリカ・カリブ海諸国のマクロ経済見通し 141
10.6 中東・アフリカ 143
10.6.1 医療アクセスの拡大と医療投資の増加が市場を牽引 143
10.6.2 中東・アフリカのマクロ経済見通し 144
10.7 GCC諸国 146
10.7.1 ヘルスケア分野の進歩と政府投資の増加が市場を牽引 146
10.7.2 GCC諸国のマクロ経済見通し 147
11 競争環境 150
11.1 概要 150
11.2 主要プレーヤーの戦略／勝利への権利 150
11.2.1 融合生検市場における各社の戦略の概要
融合生検市場 150
11.3 収益シェア分析、2021～2023年 151
11.4 市場シェア分析、2023年 152
11.5 企業評価マトリックス：主要企業、2023年 154
11.5.1 スター企業 154
11.5.2 新興リーダー 154
11.5.3 浸透型プレーヤー 154
11.5.4 参加企業 154
11.5.5 企業フットプリント：主要プレーヤー（2023年） 156
11.5.5.1 企業フットプリント 156
11.5.5.2 地域別フットプリント 157
11.5.5.3 ルートタイプのフットプリント 158
11.5.5.4 製品フットプリント 158
11.5.5.5 アプリケーションフットプリント 159
11.5.5.6 エンドユーザーのフットプリント 159
11.6 企業評価マトリクス：新興企業／SM（2023年） 160
11.6.1 先進企業 160
11.6.2 スタートアップ企業 160
11.6.3 レスポンシブ企業 160
11.6.4 ダイナミックな企業 160
11.6.5 競争ベンチマーク：新興企業／SM（2023年） 162
11.7 企業評価と財務指標（2024年） 163
11.8 ブランド／製品の比較 164
11.9 競争シナリオ 165
11.9.1 製品の上市と承認 165
11.9.2 取引 165
12 企業プロファイル 166
12.1 主要企業 166
Koninklijke Philips N.V. (Netherlands)
GE Healthcare (US)
KOELIS (France)
FUJIFILM Holdings Corporation (Japan)
Eigen Health (US)
Focal Healthcare (Canada)
Esaote SPA (Italy)
MTT GmbH (Germany)
MedCom (Germany)
UC-CARE Medical Systems (US)
Biobot Surgical (Singapore)
Canon Inc. (Japan)
and Shenzhen Mindray Bio-Medical Electronics Co.Ltd. (China)
13 付録 188
13.1 ディスカッションガイド 188
13.2 Knowledgestore： マーケットサ ンドマーケッツの購読ポータル 192
13.3 カスタマイズオプション 194
13.4 関連レポート 195
13.5 著者の詳細 196
The old population is causing a rise in age-related health conditions, such as prostate cancer, which predominantly affects older men. As these elderly individuals grows globally, the incidence of prostate cancer is also expected to increase leading to increased demand for advanced diagnostic technologies such as fusion biopsy. The increase in demand is especially seen in areas with older populations, like Europe and North America. These regions have healthcare systems that are better able to use advanced technologies like fusion biopsy.
“The equipment segment is projected to witness the highest growth rate in the fusion biopsy market, by product, during the forecast period.”
Based on product, the fusion biopsy market is segmented into equipment and consumables. The growth of equipment segment is owing to their ability to combine high-resolution imaging with real-time ultrasound for precise targeting of suspicious lesions. The demand for these equipment is fueled by the increasing prevalence of prostate cancer, the adoption of minimally invasive procedures, and ongoing technological advancements, such as AI integration for better lesion detection, further accelerates the growth of this segment.
“In 2023, the prostate cancer segment accounted for the largest share of the fusion biopsy market, by application.”
Prostate cancer and other applications make up the application-based segments of the fusion biopsy market. Market share for fusion biopsy was highest in the prostate cancer in 2023. The high incidence of prostate cancer worldwide and the efficiency of fusion biopsy in identifying these clinically relevant malignancies are the primary causes of this high percentage. Improvements in imaging technology and growing awareness of early detection further support this the lead, guaranteeing its sustained market leadership in fusion biopsy.
“The Asia Pacific region is projected to witness highest growth rate in the fusion biopsy market during the forecast period”
The global fusion biopsy market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the fusion biopsy market is expected to grow at the fastest rate in the Asia Pacific region. The rising healthcare investments, a growing prevalence of cancers like prostate cancer, and a large aging population vulnerable to cancer contribute to the significant market growth in the Aisa Pacific region during the projected period.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America – 35%, Europe – 31%, Asia Pacific – 22%, Latin America – 9%, Middle East & Africa – 2%, and the GCC Countries – 1%
Lists of Companies Profiled in the Report:
Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), MedCom (Germany), UC-CARE Medical Systems (US), Biobot Surgical (Singapore), Canon Inc. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
Research Coverage:
In this report, the fusion biopsy market has been categorized based on product (equipment and consumables), end user (hospitals and other end users), route type (transsrectal, transperineal, and other route types), application (prostate cancer and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the fusion biopsy market's expansion is included in detail in this study. An exhaustive study of the key players in the fusion biopsy market has been done to provide insights into their business profile, products offered, noteworthy strategies, collaborations, and other recent activities pertaining to the market.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall fusion biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.
The report provides insights on the following pointers:
• Analysis of key drivers: (Increasing prevalence of prostate cancer and growing gearitric population, availability of reimbursements and investments by public and private sector, and rising prevalence of minimally invasive surgery), restraints (High cost of fusio biopsy system and alternative methods for fusion biopsy), opportunities (Rise in prevalence of prostate cancer in emerging economies and technological advancements in fusion biopsy devices), and challenges (Paucity of skilled professionals and limited reimbursement in few countries) influencing the growth of the in fusion biopsy market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research development activities, and new product launches in the fusion biopsy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the fusion biopsy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the fusion biopsy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), and KOELIS (France) are among others, in the fusion biopsy market strategies.
1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.3 STUDY SCOPE 21
1.3.1 MARKETS COVERED & REGIONAL SCOPE 21
1.3.2 INCLUSIONS & EXCLUSIONS 22
1.3.3 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 23
1.5 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 26
2.1.2.1 Primary sources 26
2.1.2.2 Key data from primary sources 27
2.1.2.3 Key industry insights 28
2.1.2.4 Breakdown of primary interviews 28
2.2 MARKET SIZE ESTIMATION 29
2.2.1 BOTTOM-UP APPROACH 29
2.2.1.1 Approach 1: Company revenue estimation approach 30
2.2.2 TOP-DOWN APPROACH 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 36
2.4 MARKET SHARE ANALYSIS 37
2.5 STUDY ASSUMPTIONS 37
2.6 GROWTH RATE ASSUMPTIONS 37
2.7 RESEARCH LIMITATIONS 38
2.7.1 METHODOLOGY-RELATED LIMITATIONS 38
2.7.2 SCOPE-RELATED LIMITATIONS 38
2.8 RISK ASSESSMENT 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 43
4.1 FUSION BIOPSY MARKET OVERVIEW 43
4.2 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION AND COUNTRY (2023) 44
4.3 FUSION BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 44
4.4 FUSION BIOPSY MARKET: REGIONAL MIX (2024–2029) 45
4.5 FUSION BIOPSY MARKET: DEVELOPED VS. DEVELOPING MARKETS 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
5.2.1 DRIVERS 47
5.2.1.1 Increasing prevalence of prostate cancer and growing
geriatric population 47
5.2.1.2 Availability of reimbursements and investments by public
and private sectors 48
5.2.1.3 Rising prevalence of minimally invasive surgery 48
5.2.2 RESTRAINTS 49
5.2.2.1 High costs of fusion biopsy systems 49
5.2.2.2 Alternative methods for fusion biopsy 49
5.2.3 OPPORTUNITIES 50
5.2.3.1 Rise in prevalence of prostate cancer in emerging economies 50
5.2.3.2 Technological advancements in fusion biopsy devices 50
5.2.4 CHALLENGES 51
5.2.4.1 Paucity of skilled professionals 51
5.2.4.2 Limited reimbursement in few countries 52
5.3 PRICING ANALYSIS 52
5.3.1 PRICING ANALYSIS, BY REGION 52
5.3.2 PRICING ANALYSIS, BY PRODUCT 53
5.4 VALUE CHAIN ANALYSIS 53
5.5 SUPPLY CHAIN ANALYSIS 54
5.6 ECOSYSTEM ANALYSIS 55
5.6.1 FUSION BIOPSY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 56
5.7 PORTER’S FIVE FORCES ANALYSIS 57
5.7.1 THREAT OF NEW ENTRANTS 58
5.7.2 THREAT OF SUBSTITUTES 58
5.7.3 BARGAINING POWER OF BUYERS 58
5.7.4 BARGAINING POWER OF SUPPLIERS 59
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 59
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 59
5.8.2 BUYING CRITERIA 60
5.9 REGULATORY LANDSCAPE 61
5.9.1 NORTH AMERICA 61
5.9.1.1 US 61
5.9.1.2 Canada 62
5.9.2 EUROPE 62
5.9.3 ASIA PACIFIC 63
5.9.3.1 Japan 63
5.9.3.2 China 64
5.9.3.3 India 65
5.9.4 LATIN AMERICA 66
5.9.4.1 BRAZIL 66
5.9.4.2 MEXICO 66
5.9.5 MIDDLE EAST 66
5.9.6 AFRICA 67
5.9.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 67
5.10 TRADE ANALYSIS 69
5.10.1 TRADE ANALYSIS FOR FUSION BIOPSY MARKET 69
5.11 PATENT ANALYSIS 70
5.12 KEY CONFERENCES AND EVENTS IN 2024–2026 71
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 72
5.14 TECHNOLOGY ANALYSIS 73
5.14.1 KEY TECHNOLOGIES 73
5.14.1.1 MRI-ultrasound fusion imaging 73
5.14.2 COMPLEMENTARY TECHNOLOGIES 73
5.14.2.1 Liquid biopsy 73
5.14.2.1.1 Digital droplet PCR 73
5.14.2.1.2 Tagged-amplicon deep sequencing 74
5.15 INVESTMENT & FUNDING SCENARIO 74
5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE ON FUSION BIOPSY MARKET 74
6 FUSION BIOPSY MARKET, BY ROUTE TYPE 75
6.1 INTRODUCTION 76
6.2 TRANSRECTAL 76
6.2.1 HEIGHTENED POTENTIAL FOR SERIOUS INFECTIONS TO
HINDER MARKET GROWTH 76
6.3 TRANSPERINEAL 78
6.3.1 IMPROVED CANCER DETECTION THROUGH COMBINATION OF MRI AND ULTRASOUND TO FUEL MARKET GROWTH 78
6.4 OTHER ROUTE TYPES 80
7 FUSION BIOPSY MARKET, BY APPLICATION 83
7.1 INTRODUCTION 84
7.2 PROSTATE CANCER 84
7.2.1 PRECISE AND RELIABLE RESULTS OF PROSTATE FUSION BIOPSY TO ACCELERATE MARKET GROWTH 84
7.3 OTHER APPLICATIONS 87
8 FUSION BIOPSY MARKET, BY PRODUCT 89
8.1 INTRODUCTION 90
8.2 EQUIPMENT 90
8.2.1 SUBSTANTIAL INITIAL INVESTMENTS TO ENSURE MARKET GROWTH 90
8.3 CONSUMABLES 93
8.3.1 INCREASING APPLICATION OF INNOVATIVE TECHNOLOGIES AND METHODOLOGIES TO PROPEL MARKET GROWTH 93
9 FUSION BIOPSY MARKET, BY END USER 96
9.1 INTRODUCTION 97
9.2 HOSPITALS 97
9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO
PROMOTE MARKET GROWTH 97
9.3 OTHER END USERS 99
10 FUSION BIOPSY MARKET, BY REGION 102
10.1 INTRODUCTION 103
10.2 NORTH AMERICA 103
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 104
10.2.2 US 107
10.2.2.1 Funding for cancer research and availability of technologically advanced products to propel market growth 107
10.2.3 CANADA 109
10.2.3.1 Surging need for advanced diagnostic solutions to drive market 109
10.3 EUROPE 111
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 112
10.3.2 GERMANY 114
10.3.2.1 Rising healthcare expenditure and increasing incidence of cancer to bolster market growth 114
10.3.3 UK 116
10.3.3.1 Enhanced clinical infrastructure to accelerate fusion biopsy adoption 116
10.3.4 FRANCE 118
10.3.4.1 Effective reimbursement policies and government support for surgical product manufacturers to augment market 118
10.3.5 ITALY 120
10.3.5.1 Rising healthcare demands of geriatric population to
support market growth 120
10.3.6 SPAIN 122
10.3.6.1 Improved healthcare infrastructure and rising geriatric demographics to boost market 122
10.3.7 REST OF EUROPE 124
10.4 ASIA PACIFIC 127
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 127
10.4.2 CHINA 130
10.4.2.1 Increasing disposable income of middle-class population and rising diagnostic procedures to boost market 130
10.4.3 JAPAN 132
10.4.3.1 Robust healthcare system and surging need for precise early cancer detection to support market growth 132
10.4.4 INDIA 134
10.4.4.1 Large patient population and increasing healthcare
investments to drive market 134
10.4.5 REST OF ASIA PACIFIC 136
10.5 LATIN AMERICA 139
10.5.1 LOW FOCUS ON INFRASTRUCTURAL IMPROVEMENT AND POOR DISTRIBUTION OF RESOURCES LIKELY TO HINDER MARKET GROWTH 139
10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA & CARIBBEAN 141
10.6 MIDDLE EAST & AFRICA 143
10.6.1 EXPANDING ACCESS TO HEALTHCARE AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET 143
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 144
10.7 GCC COUNTRIES 146
10.7.1 ADVANCEMENTS AND INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO PROPEL MARKET 146
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 147
11 COMPETITIVE LANDSCAPE 150
11.1 OVERVIEW 150
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 150
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN
FUSION BIOPSY MARKET 150
11.3 REVENUE SHARE ANALYSIS, 2021–2023 151
11.4 MARKET SHARE ANALYSIS, 2023 152
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 154
11.5.1 STARS 154
11.5.2 EMERGING LEADERS 154
11.5.3 PERVASIVE PLAYERS 154
11.5.4 PARTICIPANTS 154
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 156
11.5.5.1 Company footprint 156
11.5.5.2 Region footprint 157
11.5.5.3 Route type footprint 158
11.5.5.4 Product footprint 158
11.5.5.5 Application footprint 159
11.5.5.6 End user footprint 159
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 160
11.6.1 PROGRESSIVE COMPANIES 160
11.6.2 STARTING BLOCKS 160
11.6.3 RESPONSIVE COMPANIES 160
11.6.4 DYNAMIC COMPANIES 160
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 162
11.7 COMPANY VALUATION & FINANCIAL METRICS, 2024 163
11.8 BRAND/PRODUCT COMPARISON 164
11.9 COMPETITIVE SCENARIO 165
11.9.1 PRODUCT LAUNCHES & APPROVALS 165
11.9.2 DEALS 165
12 COMPANY PROFILES 166
12.1 KEY PLAYERS 166
12.1.1 KONINKLIJKE PHILIPS N.V. 166
12.1.1.1 Business overview 166
12.1.1.2 Products offered 167
12.1.1.3 MnM view 168
12.1.1.3.1 Key strengths 168
12.1.1.3.2 Strategic choices 168
12.1.1.3.3 Weaknesses & competitive threats 168
12.1.2 GE HEALTHCARE 169
12.1.2.1 Business overview 169
12.1.2.2 Products offered 170
12.1.2.3 MnM view 171
12.1.2.3.1 Right to win 171
12.1.2.3.2 Strategic choices 171
12.1.2.3.3 Weaknesses & competitive threats 171
12.1.3 KOELIS 172
12.1.3.1 Business overview 172
12.1.3.2 Products offered 172
12.1.3.3 Recent developments 173
12.1.3.3.1 Deals 173
12.1.3.4 MnM view 173
12.1.3.4.1 Right to win 173
12.1.3.4.2 Strategic choices 173
12.1.3.4.3 Weaknesses & competitive threats 173
12.1.4 FUJIFILM HOLDINGS CORPORATION 174
12.1.4.1 Business overview 174
12.1.4.2 Products offered 175
12.1.4.3 Recent developments 176
12.1.4.3.1 Product launches & approvals 176
12.1.5 CANON INC. 177
12.1.5.1 Business overview 177
12.1.5.2 Products offered 178
12.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 179
12.1.6.1 Business overview 179
12.1.6.2 Products offered 180
12.1.7 ESAOTE SPA 181
12.1.7.1 Business overview 181
12.1.7.2 Products offered 181
12.1.8 EIGEN HEALTH 182
12.1.8.1 Business overview 182
12.1.8.2 Products offered 182
12.2 OTHER PLAYERS 184
12.2.1 FOCAL HEALTHCARE 184
12.2.2 MTT GMBH 185
12.2.3 MEDCOM 186
12.2.4 UC-CARE MEDICAL SYSTEMS 187
12.2.5 BIOBOT SURGICAL 187
13 APPENDIX 188
13.1 DISCUSSION GUIDE 188
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 192
13.3 CUSTOMIZATION OPTIONS 194
13.4 RELATED REPORTS 195
13.5 AUTHOR DETAILS 196
❖ 世界の融合生検市場に関するよくある質問(FAQ) ❖
・融合生検の世界市場規模は？
→MarketsandMarkets社は2024年の融合生検の世界市場規模を6.5億ドルと推定しています。
・融合生検の世界市場予測は？
→MarketsandMarkets社は2029年の融合生検の世界市場規模を9.1億ドルと予測しています。
・融合生検市場の成長率は？
→MarketsandMarkets社は融合生検の世界市場が2024年～2029年に年平均7.1%成長すると予測しています。
・世界の融合生検市場における主要企業は？
→MarketsandMarkets社は「Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), MedCom (Germany), UC-CARE Medical Systems (US), Biobot Surgical (Singapore), Canon Inc. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)など ...」をグローバル融合生検市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
